RPRX (Pharmaceuticals) Stock Valuation & Fair Value Trading above fair value
RPRX (Pharmaceuticals) trades at a blended P/E of 11.6, about 20% above its historical normal valuation, with a forward growth estimate of 10.5% and a PEG of 1.11. Analysts' one-year estimates have been hit 40% of the time.
Valuation flags
- Overvalued by 20%
Frequently asked questions
Is RPRX overvalued?
At a blended P/E of 11.6 versus its historical normal P/E of 9.7, RPRX trades about 20% above its typical valuation, with a PEG of 1.11 on 10.5% forward growth. tickerseer currently rates it trading above fair value.
What is RPRX's fair value and PEG?
RPRX trades at a blended P/E of 11.6 against a historical normal P/E of 9.7, a PEG of 1.11, and a forward growth estimate of 10.5%.
Has tickerseer's rating of RPRX changed?
tickerseer's rating has been trading above fair value since 2026-07-31.
Industry: Pharmaceuticals. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in the paid plan.
It's free, and you can unsubscribe any time. Educational content, not investment advice.